Skip to main content

Table 2 Patient characters and tumor-specific factors of the study population

From: The ICU-venous thromboembolism score and tumor grade can predict inhospital venous thromboembolism occurrence in critical patients with tumors

Characteristics

With VTE

N = 312

Without VTE

N = 248

P

Patient data

 Age, y, IQR

66.0 (60.0–73.0)

64.0 (57.0–70.8)

0.001

  ≥ 65 years, N (%)

190 (60.9)

114 (46.0)

< 0.001

 Male, N (%)

199 (63.8)

166 (66.9)

0.437

 BMI, ± SD (kg/m2)

24.2 ± 3.8

23.6 ± 4.0

0.077

  ≥ 25 (kg/m2), N (%)

119 (38.1)

82 (33.1)

0.214

 Smoking history, N (%)

119 (38.1)

105 (42.3)

0.314

 Past alcohol use, N (%)

79 (25.3)

64 (25.8)

0.896

Comorbidities, N (%)

 Diabetes

57 (18.3)

55 (22.2)

0.251

 Hypertension

135 (43.3)

98 (39.5)

0.371

 Prior VTE

56 (17.9)

3 (1.2)

< 0.001

 MACCE

55 (17.6)

51 (20.6)

0.378

Causes of ICU admission

  

0.002

 Surgical, N (%)

205 (65.7)

192 (77.4)

 

 Medical, N (%)

107 (34.3)

56 (22.6)

 

Tumor category, N (%)

  

0.244

 Lung cancer

17 (5.4)

16 (6.5)

 

 Hepatobiliary and pancreatic tumors

28 (9.0)

15 (6.0)

 

 Tumors of digestive system

199 (63.8)

167 (67.3)

 

 Breast cancer

15 (4.8)

3 (1.2)

 

 Gynecological tumors

11 (3.5)

10 (4.0)

 

 Retroperitoneal masses

21 (6.7)

19 (7.7)

 

 Others*

21 (6.7)

18 (7.3)

 

Stagea

  

0.513

 1–3, N (%)

216 (71.1)

165 (68.5)

 

 4, N (%)

88 (28.9)

76 (31.5)

 

Gradea

  

0.002

 1–2, N (%)

160 (52.6)

158 (65.6)

 

 3–4, N (%)

144 (47.4)

83 (34.4)

 

Baseline test results

 WBC, ×109/L, IQR

5.9 (4.6–7.3)

5.7 (4.6–7.6)

0.755

 Hemoglobin, g/L, IQR

124.0 (103.3–141.0)

123.5 (101.0–141.8)

0.984

 Platelet, ×109/L, IQR

198.0 (153.3–266.8)

181.5 (137.5–251.0)

0.044

 Creatinine, μmol/L, IQR

64.0 (53.0–74.0)

67.0 (55.0–81.0)

0.742

 Albumin, g/L, IQR

41.4 (37.9–44.7)

41.9 (37.4–44.8)

0.479

 Bilirubin, μmol/L, IQR

12.6 (9.1–17.6)

12.1 (8.4–16.7)

0.120

 Glucose, mmol/L, IQR

5.7 (5.1–6.9)

5.6 (5.0–6.8)

0.985

 TC, mmol/L, IQRb

4.37 (3.81–5.17)

4.26 (3.52–4.98)

0.039

 TG, mmol/L, IQRb

1.18 (0.85–1.74)

1.24 (0.85–1.85)

0.299

ABO blood group, N (%)c

  

0.216

 A

86 (27.8)

85 (34.4)

 

 B

100 (32.4)

66 (26.7)

 

 AB

32 (10.4)

31 (12.6)

 

 O

91 (29.4)

65 (26.3)

 

APTT, s, IQR

30.1 (27.6–34.0)

31.0 (28.5–35.3)

0.362

INR, IQR

1.02 (0.97–1.08)

1.04 (0.98–1.14)

0.131

D-dimer, μmol/L, IQRd

1.18 (0.75–2.51)

1.03 (0.67–2.12)

0.052

APECHE II

10 (7–13)

9 (7–12)

0.145

  1. *Other tumor types included the following: thyroid cancer, prostatic cancer, malignant melanoma, lymphoma, and benign tumor. aBenign lesion was occurred in 15 patients. bBaseline TC and TG examination were not available for 19 individuals. cABO blood group was not available for 4 individuals. dOne-hundred seventy-five patients did not receive D-dimer examination at admission. Data are n (% of total available data within each column), mean ± SD, or median (IQR)